Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.
AVROBIO, Inc. (AVRO) is a clinical-stage biopharmaceutical company pioneering gene and cell therapies for rare diseases and cancer. This page aggregates official announcements, clinical trial updates, and strategic developments critical to understanding the company's progress.
Investors and researchers will find verified updates on therapy pipelines, regulatory milestones, and scientific collaborations. Content spans phase trial results, manufacturing advancements, and partnership announcements, providing a holistic view of AVROBIO's position in the gene therapy landscape.
All materials are sourced from company filings and accredited industry publications. Bookmark this page for streamlined access to AVROBIO's latest developments, or subscribe for real-time updates on groundbreaking therapeutic innovations.
AVROBIO, a clinical-stage gene therapy company, has awarded a stock option to a new employee for the purchase of 22,000 shares at an exercise price of $1.25 per share. This grant, made on April 1, 2022, serves as an inducement for employment under the company’s Inducement Plan and adheres to Nasdaq regulations. The option vests over four years, with 25% vesting after one year, contingent upon the employee's ongoing service. AVROBIO focuses on gene therapies for genetic diseases and aims to offer innovative solutions through its plato® platform.
AVROBIO, a clinical-stage gene therapy company, will feature CEO Geoff MacKay at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 9:30 a.m. ET. A live webcast of his presentation will be accessible on the AVROBIO website and archived for 30 days. The company aims to develop personalized gene therapies targeting genetic diseases, utilizing the plato® gene therapy platform. AVROBIO focuses on conditions such as cystinosis and Gaucher disease, seeking to provide durable therapeutic solutions.
AVROBIO reported significant progress in its gene therapy programs during 2021, with interim data showing sustained engraftment in cystinosis patients post-gene therapy. The company dosed a third patient in its Gaucher disease trial and plans regulatory interactions for clinical development in multiple rare diseases. Financially, AVROBIO reported a net loss of $28.2 million for Q4 2021 and $119.1 million for the full year, but maintains a strong cash position of $189.6 million, supporting operations into Q1 2024.
AVROBIO, a leading clinical-stage gene therapy company, has announced its participation in two significant investor conferences. The Cowen 42nd Annual Health Care Conference will feature a panel on orphan CNS on March 8, 2022, at 2:10 p.m. ET, followed by a presentation at the Barclays Global Healthcare Conference on March 15, 2022, at 4:20 p.m. ET. Live webcasts will be available on the AVROBIO website. The company aims to deliver personalized gene therapy to treat genetic diseases, leveraging its plato® gene therapy platform.
AVROBIO reported promising interim data from a Phase 1/2 clinical trial for AVR-RD-04, a gene therapy for cystinosis. The first three patients infused have shown sustained engraftment beyond one year and remain off oral cysteamine, with a significant reduction in cystine crystals observed in skin and intestinal biopsies. No adverse events related to the therapy were recorded. This data supports a future AVROBIO-sponsored trial planned for 2023, building on the encouraging safety and efficacy indicators from the initial findings.
AVROBIO, a clinical-stage gene therapy company, announced the grant of stock options and restricted stock units (RSUs) to new employees as part of its 2019 Inducement Plan. A total of 167,000 stock options and 2,667 RSUs were awarded to incentivize employee acceptance of roles. The stock options have a 10-year term with an exercise price of $1.95 per share, reflecting the company's closing price on the grant date, February 1, 2022. Vesting is structured over four years, contingent on continued service.
AVROBIO (Nasdaq: AVRO), a clinical-stage gene therapy company, has appointed Sean O’Bryan as its new Chief Regulatory Officer. O’Bryan brings over 30 years of regulatory experience in the biotech sector, most recently at Freeline Therapeutics. His appointment is expected to enhance AVROBIO's clinical programs, particularly in lysosomal disorders such as cystinosis and Gaucher disease. CEO Geoff MacKay expressed confidence in O’Bryan's expertise to accelerate AVROBIO's mission of delivering personalized gene therapies.
AVROBIO, a clinical-stage gene therapy company, announced that Dr. Azadeh Golipour, its CTO, will present at Cowen's 2nd Annual Genetic Medicines Summit on February 3, 2022, at 2:00 p.m. ET. The company aims to address genetic diseases with its plato® gene therapy platform, focusing on conditions like cystinosis and Gaucher disease. AVROBIO is headquartered in Cambridge, Mass., with a presence in Toronto.
The company emphasizes the potential benefits of its gene therapy candidates, while also acknowledging various risks and uncertainties.
AVROBIO announced the presentation of updated clinical data from its Phase 1/2 trial for cystinosis on
AVROBIO, a clinical-stage gene therapy company, announced the grant of non-statutory stock options for up to 30,500 shares to three new employees as inducement awards. The options were approved by the Compensation Committee and were granted on January 3, 2022, with an exercise price of $4.04 per share. These options have a 10-year term and vest over four years. AVROBIO aims to advance gene therapy, notably in cystinosis and Gaucher disease, leveraging its plato® platform.
